ID

31876

Description

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00847886

Link

https://clinicaltrials.gov/show/NCT00847886

Keywords

Versions (1)
  1. 10/6/18 10/6/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

October 6, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Rheumatoid Arthritis NCT00847886

English

Eligibility Rheumatoid Arthritis NCT00847886

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
males and females ≥ 18 years old
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
must be willing to practice 2 adequate methods of contraception for the duration of the study
Description

Contraceptive methods Quantity Willing

Data type

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0600109
rheumatoid arthritis present for at least 3 months; functional class i, ii, or iii as defined by acr criteria
Description

Rheumatoid Arthritis Functional Status Class Disease length

Data type

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0598463
UMLS CUI [1,3]
C0456387
UMLS CUI [1,4]
C0872146
treatment with methotrexate (7.5 to 25 mg per week) for at least the last 3 months, and currently receiving stable dose methotrexate for at least one month prior to the start of the study
Description

Methotrexate U/week | Methotrexate Dose Stable

Data type

boolean

Alias
UMLS CUI [1,1]
C0025677
UMLS CUI [1,2]
C0560588
UMLS CUI [2,1]
C0025677
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
ability to provide written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
women who are pregnant or nursing
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
history of other current inflammatory arthritis
Description

Arthritis Other

Data type

boolean

Alias
UMLS CUI [1,1]
C0003864
UMLS CUI [1,2]
C0205394
history of opportunistic infection
Description

Opportunistic Infection

Data type

boolean

Alias
UMLS CUI [1]
C0029118
history of recurrent infections or current infection 2 weeks prior to start of study
Description

Recurrent infections | Communicable Disease

Data type

boolean

Alias
UMLS CUI [1]
C0239998
UMLS CUI [2]
C0009450
presence of significant, uncontrolled medical problems
Description

Medical Problem Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C1254481
UMLS CUI [1,2]
C0205318
treatment with any disease-modifying anti-rheumatoid drugs other than methotrexate within 4 weeks prior to start of study
Description

Antirheumatic Drugs, Disease-Modifying | Exception Methotrexate

Data type

boolean

Alias
UMLS CUI [1]
C0242708
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025677
use of chondroitin sulfate, glucosamine sulfate, minocycline, or matrix metalloproteinase inhibitors, h-2 blockers, proton pump inhibitors, or misoprostol within 4 weeks prior to study start
Description

Chondroitin Sulfates | Glucosamine Sulfate | Minocycline | Matrix Metalloproteinase Inhibitors | H2 blockers | Proton Pump Inhibitors | Misoprostol

Data type

boolean

Alias
UMLS CUI [1]
C0008466
UMLS CUI [2]
C0017720
UMLS CUI [3]
C0026187
UMLS CUI [4]
C1513016
UMLS CUI [5]
C0019593
UMLS CUI [6]
C0358591
UMLS CUI [7]
C0085174
receipt of live vaccine within 8 weeks prior to study start
Description

Live vaccine

Data type

boolean

Alias
UMLS CUI [1]
C0042211
rheumatoid arthritis, functional class iv as defined by acr criteria
Description

Rheumatoid Arthritis Functional Status Class

Data type

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0598463
UMLS CUI [1,3]
C0456387
Back to the top of the page

Similar models

Eligibility Rheumatoid Arthritis NCT00847886

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
males and females ≥ 18 years old
boolean
C0001779 (UMLS CUI [1])
Contraceptive methods Quantity Willing
Item
must be willing to practice 2 adequate methods of contraception for the duration of the study
boolean
C0700589 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
Rheumatoid Arthritis Functional Status Class Disease length
Item
rheumatoid arthritis present for at least 3 months; functional class i, ii, or iii as defined by acr criteria
boolean
C0003873 (UMLS CUI [1,1])
C0598463 (UMLS CUI [1,2])
C0456387 (UMLS CUI [1,3])
C0872146 (UMLS CUI [1,4])
Methotrexate U/week | Methotrexate Dose Stable
Item
treatment with methotrexate (7.5 to 25 mg per week) for at least the last 3 months, and currently receiving stable dose methotrexate for at least one month prior to the start of the study
boolean
C0025677 (UMLS CUI [1,1])
C0560588 (UMLS CUI [1,2])
C0025677 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Informed Consent
Item
ability to provide written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
women who are pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Arthritis Other
Item
history of other current inflammatory arthritis
boolean
C0003864 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Opportunistic Infection
Item
history of opportunistic infection
boolean
C0029118 (UMLS CUI [1])
Recurrent infections | Communicable Disease
Item
history of recurrent infections or current infection 2 weeks prior to start of study
boolean
C0239998 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
Medical Problem Uncontrolled
Item
presence of significant, uncontrolled medical problems
boolean
C1254481 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Antirheumatic Drugs, Disease-Modifying | Exception Methotrexate
Item
treatment with any disease-modifying anti-rheumatoid drugs other than methotrexate within 4 weeks prior to start of study
boolean
C0242708 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025677 (UMLS CUI [2,2])
Chondroitin Sulfates | Glucosamine Sulfate | Minocycline | Matrix Metalloproteinase Inhibitors | H2 blockers | Proton Pump Inhibitors | Misoprostol
Item
use of chondroitin sulfate, glucosamine sulfate, minocycline, or matrix metalloproteinase inhibitors, h-2 blockers, proton pump inhibitors, or misoprostol within 4 weeks prior to study start
boolean
C0008466 (UMLS CUI [1])
C0017720 (UMLS CUI [2])
C0026187 (UMLS CUI [3])
C1513016 (UMLS CUI [4])
C0019593 (UMLS CUI [5])
C0358591 (UMLS CUI [6])
C0085174 (UMLS CUI [7])
Live vaccine
Item
receipt of live vaccine within 8 weeks prior to study start
boolean
C0042211 (UMLS CUI [1])
Rheumatoid Arthritis Functional Status Class
Item
rheumatoid arthritis, functional class iv as defined by acr criteria
boolean
C0003873 (UMLS CUI [1,1])
C0598463 (UMLS CUI [1,2])
C0456387 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial